

# Min Hee Hong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8851689/publications.pdf>

Version: 2024-02-01

86  
papers

2,440  
citations

257450

24  
h-index

233421

45  
g-index

89  
all docs

89  
docs citations

89  
times ranked

3876  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 1104-1113.	1.2	205
2	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. <i>Scientific Reports</i> , 2016, 6, 36956.	3.3	196
3	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR/MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. <i>Cancer Discovery</i> , 2020, 10, 1194-1209.	9.4	158
4	Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1550-1563.	7.7	99
5	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1681-1690.	10.7	92
6	Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. <i>Immune Network</i> , 2020, 20, e10.	3.6	86
7	Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1065-1073.	0.8	79
8	Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1373-1382.	1.1	77
9	YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2575-2587.	7.0	71
10	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. <i>Clinical Cancer Research</i> , 2021, 27, 2168-2178.	7.0	67
11	Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1613-1623.	2.5	66
12	Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front Mutant ROS1-Rearranged Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3287-3295.	7.0	66
13	Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea. <i>Cancer Research and Treatment</i> , 2009, 41, 67.	3.0	63
14	Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles. <i>Oncology</i> , 2011, 80, 395-405.	1.9	48
15	Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 1250-1259.	1.2	47
16	SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA8507-LBA8507.	1.6	46
17	Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 9050.	3.3	43
18	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 558-567.	1.1	43

#	ARTICLE	IF	CITATIONS
19	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. <i>Cancer Research</i> , 2018, 78, 3350-3362.	0.9	42
20	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK rearranged lung cancer. <i>EMBO Molecular Medicine</i> , 2019, 11, e10581.	6.9	40
21	Clinical Value of Ezrin Expression in Primary Osteosarcoma. <i>Cancer Research and Treatment</i> , 2009, 41, 138.	3.0	39
22	Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy. <i>Lung Cancer</i> , 2019, 136, 30-36.	2.0	32
23	The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2020, 12, 6426-6434.	1.4	30
24	Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021, 143, 113-126.	2.8	30
25	ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. <i>Oncogene</i> , 2018, 37, 377-388.	5.9	29
26	A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4027-4027.	1.6	28
27	Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. <i>Head and Neck</i> , 2018, 40, 55-62.	2.0	26
28	Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 131, 139-146.	2.0	25
29	Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials. <i>Cancer Research and Treatment</i> , 2009, 41, 196.	3.0	25
30	Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy. <i>Radiotherapy and Oncology</i> , 2022, 168, 1-7.	0.6	25
31	A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. <i>Lung Cancer</i> , 2019, 134, 46-51.	2.0	24
32	Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 797-805.	2.3	23
33	Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival. <i>Lung Cancer</i> , 2018, 121, 12-17.	2.0	23
34	Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. <i>Lung Cancer</i> , 2018, 124, 168-178.	2.0	23
35	Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2019, 60, 525.	2.2	23
36	Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1093-1101.	4.2	23

#	ARTICLE	IF	CITATIONS
37	Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. <i>Oncotarget</i> , 2017, 8, 65111-65122.	1.8	23
38	Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma. <i>Scientific Reports</i> , 2019, 9, 19909.	3.3	18
39	Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck. <i>British Journal of Cancer</i> , 2020, 123, 1720-1729.	6.4	18
40	Prognosis of pN3 Stage Gastric Cancer. <i>Cancer Research and Treatment</i> , 2009, 41, 73.	3.0	18
41	Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response. <i>British Journal of Cancer</i> , 2020, 122, 1649-1660.	6.4	17
42	Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA <i>in situ</i> hybridization. <i>Oncotarget</i> , 2017, 8, 87234-87243.	1.8	17
43	The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges. <i>Frontiers in Oncology</i> , 2022, 12, 811247.	2.8	17
44	Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in <i>ALK</i> -positive non-small-cell lung cancer. , 2020, 8, e000970.		16
45	Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021, 153, 179-189.	2.8	16
46	High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 20197.	3.3	15
47	Establishment and characterization of patient-derived xenografts as preclinical models for head and neck cancer. <i>BMC Cancer</i> , 2020, 20, 316.	2.6	14
48	Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma. <i>Scientific Reports</i> , 2021, 11, 8551.	3.3	13
49	Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. <i>PLoS ONE</i> , 2019, 14, e0224379.	2.5	12
50	The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer. <i>Experimental and Molecular Medicine</i> , 2022, 54, 12-22.	7.7	12
51	Incidence, in-hospital mortality, and readmission among patients with alcoholic hepatitis in Korea: A nationwide study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 747-754.	2.8	11
52	Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Cancer</i> , 2020, 126, 4521-4531.	4.1	10
53	Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210791.	3.2	10
54	A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11). <i>Clinical Cancer Research</i> , 2022, 28, 4240-4247.	7.0	10

#	ARTICLE	IF	CITATIONS
55	P3.02b-119 YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1265-S1266.	1.1	8
56	Povidone-iodine for the management of oral mucositis during cancer therapy. <i>Oncology Reviews</i> , 2017, 11, 341.	1.8	8
57	A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 7012-7020.	2.8	8
58	Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 799-808.	2.3	7
59	Recurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case Report. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 864-867.	1.8	7
60	Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2021, 13, 3096.	3.7	7
61	Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor. <i>Yonsei Medical Journal</i> , 2022, 63, 42.	2.2	7
62	Predicting treatment outcomes using <sup>18</sup> F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110687.	3.2	7
63	Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity. <i>Frontiers in Oncology</i> , 2022, 12, 821391.	2.8	6
64	SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models. <i>Clinical and Translational Immunology</i> , 2022, 11, e1364.	3.8	6
65	Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 405-414.	2.3	5
66	Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents. <i>Kidney Research and Clinical Practice</i> , 2021, 40, 344-354.	2.2	5
67	Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2741-2750.	2.5	4
68	Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2459-2469.	2.5	3
69	Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy. <i>Cancers</i> , 2021, 13, 2549.	3.7	3
70	Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study. <i>Cancers</i> , 2021, 13, 3681.	3.7	3
71	Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate. <i>PLoS ONE</i> , 2019, 14, e0214291.	2.5	2
72	Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962097957.	1.7	2

#	ARTICLE	IF	CITATIONS
73	Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients. <i>Scientific Reports</i> , 2021, 11, 7435.	3.3	2
74	Abstract 1106: BRAF and EGFR fusion as a novel mechanism of resistance mechanism to Lazertinib, 3rd-generation EGFR-TKI, in EGFR-mutant NSCLC. <i>Cancer Research</i> , 2021, 81, 1106-1106.	0.9	2
75	YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9033-9033.	1.6	2
76	Disproportional enrichment of FoxP3 <sup>+</sup> CD4 <sup>+</sup> regulatory T cells shapes a suppressive tumour microenvironment in head and neck squamous cell carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, e753.	4.0	2
77	Mesoporous Thin Films: Thermoelectric Application. <i>Applied Mechanics and Materials</i> , 0, 260-261, 34-39.	0.2	1
78	A study of senaparib in combination with temozolomide for the treatment of patients with advanced solid tumors and extensive-stage small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3102-3102.	1.6	1
79	Abstract LB515A: A MET targeting biparatopic antibody-drug conjugates (ADC), REGN5093-M114, has an antitumor efficacy in NSCLC harboring MET gene alterations. <i>Cancer Research</i> , 2022, 82, LB515A-LB515A.	0.9	1
80	Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC): Updated results with high dimensional profiling of circulating immune cells.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6072-6072.	1.6	1
81	Synthesize of Mesoporous ZnO Thin Films and Gas Sensing Property. <i>Advanced Materials Research</i> , 2014, 960-961, 157-160.	0.3	0
82	MAPK-signaling inhibition as a genome-based precision medicine in refractory osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22164-e22164.	1.6	0
83	Everolimus-associated pneumonitis in Asian metastatic renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15596-e15596.	1.6	0
84	Phase II study of afatinib in recurrent and/or metastatic esophageal squamous cell carcinoma (R/M) Tj ETQqO O O rgBT /Overlock 10 Tf 5	1.6	0
85	Abstract LB544: Targeting adaptive metabolic program as a novel treatment approach for TKIs-failed ALK-positive NSCLCs. <i>Cancer Research</i> , 2022, 82, LB544-LB544.	0.9	0
86	A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non-EGFR small cell lung cancer (NSCLC) with EGFR mutation.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9107-9107.	1.6	0